Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 18 | 2023 | 204 | 2.310 |
Why?
|
| Quality of Life | 10 | 2023 | 677 | 0.760 |
Why?
|
| Sarcoidosis | 1 | 2021 | 14 | 0.750 |
Why?
|
| Skin Diseases | 1 | 2021 | 28 | 0.740 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2018 | 3 | 0.650 |
Why?
|
| Symptom Assessment | 1 | 2018 | 21 | 0.640 |
Why?
|
| Patient Care Management | 1 | 2018 | 18 | 0.640 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2018 | 384 | 0.520 |
Why?
|
| Antibodies, Antinuclear | 2 | 2017 | 21 | 0.510 |
Why?
|
| Surveys and Questionnaires | 8 | 2023 | 1187 | 0.490 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2014 | 4 | 0.480 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2014 | 5 | 0.480 |
Why?
|
| Interleukin-10 | 1 | 2014 | 36 | 0.470 |
Why?
|
| Interferon-alpha | 1 | 2014 | 69 | 0.460 |
Why?
|
| Interleukin-6 | 1 | 2014 | 109 | 0.460 |
Why?
|
| Patient Acuity | 2 | 2018 | 9 | 0.320 |
Why?
|
| Rheumatologists | 2 | 2018 | 16 | 0.310 |
Why?
|
| Body Image | 3 | 2012 | 31 | 0.300 |
Why?
|
| Adult | 15 | 2021 | 8748 | 0.290 |
Why?
|
| Self Report | 3 | 2023 | 221 | 0.290 |
Why?
|
| Rheumatology | 3 | 2018 | 87 | 0.280 |
Why?
|
| Male | 17 | 2021 | 15871 | 0.280 |
Why?
|
| Humans | 28 | 2023 | 29851 | 0.280 |
Why?
|
| Patient Outcome Assessment | 2 | 2018 | 44 | 0.280 |
Why?
|
| Health Status | 3 | 2018 | 230 | 0.250 |
Why?
|
| Cross-Sectional Studies | 6 | 2019 | 970 | 0.240 |
Why?
|
| Female | 19 | 2021 | 16430 | 0.240 |
Why?
|
| Tuberculosis | 3 | 2009 | 25 | 0.240 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 803 | 0.210 |
Why?
|
| Pneumococcal Infections | 1 | 2021 | 9 | 0.200 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2021 | 10 | 0.200 |
Why?
|
| Middle Aged | 13 | 2021 | 9963 | 0.200 |
Why?
|
| Raynaud Disease | 1 | 2001 | 2 | 0.200 |
Why?
|
| Infliximab | 1 | 2021 | 16 | 0.190 |
Why?
|
| Quality of Health Care | 3 | 2023 | 138 | 0.190 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 1126 | 0.190 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2000 | 2 | 0.190 |
Why?
|
| United States | 5 | 2018 | 2346 | 0.180 |
Why?
|
| Skin | 1 | 2021 | 118 | 0.180 |
Why?
|
| Recurrence | 1 | 2021 | 355 | 0.180 |
Why?
|
| Psychometrics | 2 | 2018 | 264 | 0.170 |
Why?
|
| Dimethylformamide | 1 | 1999 | 1 | 0.170 |
Why?
|
| Antirheumatic Agents | 3 | 2009 | 92 | 0.170 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2018 | 12 | 0.160 |
Why?
|
| Virus Replication | 1 | 1999 | 92 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 26 | 0.160 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 39 | 0.160 |
Why?
|
| Immunoglobulin G | 2 | 2009 | 129 | 0.150 |
Why?
|
| Arthritis, Psoriatic | 2 | 2009 | 19 | 0.150 |
Why?
|
| Pain | 2 | 2019 | 397 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 148 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 24 | 0.140 |
Why?
|
| Research Design | 1 | 2018 | 214 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2019 | 468 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 129 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3561 | 0.130 |
Why?
|
| Isoniazid | 2 | 2009 | 6 | 0.130 |
Why?
|
| Osteoarthritis, Knee | 1 | 2000 | 382 | 0.130 |
Why?
|
| HIV-1 | 1 | 1999 | 451 | 0.130 |
Why?
|
| Depression | 1 | 2019 | 472 | 0.120 |
Why?
|
| Hospitals, University | 2 | 2012 | 40 | 0.120 |
Why?
|
| Aged | 5 | 2021 | 9621 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1462 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2014 | 78 | 0.120 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2013 | 11 | 0.110 |
Why?
|
| Dermatology | 1 | 2012 | 6 | 0.110 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2012 | 6 | 0.110 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2012 | 16 | 0.110 |
Why?
|
| Hospitals, County | 1 | 2012 | 4 | 0.110 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2011 | 4 | 0.100 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 9 | 0.100 |
Why?
|
| Rheumatic Diseases | 2 | 2009 | 56 | 0.100 |
Why?
|
| Physicians | 1 | 2012 | 116 | 0.090 |
Why?
|
| Benchmarking | 1 | 2010 | 42 | 0.090 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 969 | 0.090 |
Why?
|
| Transaminases | 1 | 2009 | 6 | 0.090 |
Why?
|
| Methotrexate | 1 | 2009 | 42 | 0.080 |
Why?
|
| Vasculitis | 1 | 2009 | 32 | 0.080 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2009 | 44 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2011 | 364 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 507 | 0.080 |
Why?
|
| Liver | 1 | 2009 | 175 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2018 | 3325 | 0.070 |
Why?
|
| Antitubercular Agents | 2 | 2009 | 16 | 0.070 |
Why?
|
| Heart Auscultation | 1 | 2006 | 4 | 0.070 |
Why?
|
| Pulse | 1 | 2006 | 6 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2006 | 32 | 0.070 |
Why?
|
| Teaching | 1 | 2006 | 63 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2006 | 213 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 79 | 0.050 |
Why?
|
| Vaccination | 1 | 2021 | 41 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 45 | 0.050 |
Why?
|
| Mycobacterium | 1 | 2000 | 2 | 0.050 |
Why?
|
| Pyrazinamide | 1 | 2000 | 2 | 0.050 |
Why?
|
| Streptomycin | 1 | 2000 | 2 | 0.050 |
Why?
|
| Ethambutol | 1 | 2000 | 4 | 0.050 |
Why?
|
| Rifampin | 1 | 2000 | 7 | 0.050 |
Why?
|
| Synovial Fluid | 1 | 2000 | 124 | 0.040 |
Why?
|
| HIV Core Protein p24 | 1 | 1999 | 29 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 10 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2018 | 13 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 56 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 63 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 85 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 87 | 0.040 |
Why?
|
| Workload | 1 | 2018 | 33 | 0.040 |
Why?
|
| Tuberculin Test | 2 | 2009 | 12 | 0.040 |
Why?
|
| Etanercept | 2 | 2009 | 23 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2009 | 33 | 0.040 |
Why?
|
| Cell Line | 1 | 1999 | 299 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2018 | 69 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2017 | 64 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2017 | 67 | 0.040 |
Why?
|
| Sex Factors | 1 | 2018 | 498 | 0.040 |
Why?
|
| Illinois | 1 | 2017 | 241 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 867 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2007 | 223 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 1953 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1641 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 20 | 0.030 |
Why?
|
| Disease Management | 1 | 2013 | 122 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2012 | 29 | 0.030 |
Why?
|
| Self Concept | 1 | 2012 | 46 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 399 | 0.030 |
Why?
|
| Feedback | 1 | 2012 | 32 | 0.030 |
Why?
|
| Reference Values | 1 | 2012 | 231 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 504 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 78 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 19 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2011 | 14 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 874 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 142 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 643 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 349 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 854 | 0.020 |
Why?
|
| Arthritis, Juvenile | 1 | 2009 | 8 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2009 | 19 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 4930 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1247 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 704 | 0.020 |
Why?
|
| Adolescent | 1 | 2012 | 2334 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 1969 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2009 | 685 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1824 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2006 | 33 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2006 | 58 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 117 | 0.020 |
Why?
|
| Cardiology | 1 | 2006 | 73 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 107 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 135 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 337 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 1859 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 2467 | 0.010 |
Why?
|